Driven by data from Dexcom's continuous glucose monitoring devices, customers using Rimidi's diabetes management platform will now have enhanced metrics to advance care management
ATLANTA, June 22, 2023 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management.
"As continuous glucose monitoring (CGM) gains broader adoption and becomes standard of care in patients with Type 2 Diabetes and primary care, clinicians need strategies for effectively triaging their growing population of patients using CGM and identifying appropriate steps to improve glycemic control," said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. "GRI is an exciting new tool in the toolkit for clinicians and Rimidi is committed to bringing this innovation into the clinical workflow."
The inclusion of CGM data and GRI into Rimidi's platform and clinical workflows is made possible via an enhanced integration with Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions.
Today, more than 37 million people in the US, or about 11% of the population, live with diabetes. If not properly controlled, the disease can lead to other comorbidities, such as heart disease, obesity and kidney failure, further contributing to worse health outcomes and additional healthcare costs. For these patients, taking frequent glucose level checks is critical.
Specifically, the Rimidi diabetes management platform will now include metrics for:
- Time in Range (TIR): The amount of time a patient spends in the target blood glucose range during a specified time period, often two weeks. For most patients, this is between 70 and 180 mg/dL, and is a measurement that leverages CGM data to see the number of times a patient's blood glucose level has stayed in the target range vs. been high (hyperglycemia) or low (hypoglycemia). TIR is considered the gold standard of CGM data management and interpretation today. Rimidi presents the TIR for target glucose as well as additional categories of low, very low, high and very high glucose.
- Glycemic Risk Index: A new actionable metric for describing the quality of glycemia in CGM tracking, developed by the Diabetes Technology Society. This metric can be used to assess how well a patient is doing over time, manage a population and predict outcomes in intervention studies. The composite score is also thought to better correlate with the risk of complications and help identify areas for therapy adjustment. The use of GRI in clinical practice is just beginning to gain adoption.
Rimidi's diabetes management platform combines patient-generated data from CGMs and other connected devices, with relevant clinical data in EHR systems, allowing clinicians to see all of the important data for diabetes care, including medications, latest laboratory results, and diagnoses, within their EHR, to drive patient-specific clinical actions through embedded Clinical Decision Support cards. These new enhancements will further enable clinicians to manage their diabetes patients and empower patients to make lifestyle changes.
"Adoption and application of CGM technology continues to evolve and expand. Dexcom is at the forefront of this innovation to help simplify and improve diabetes management for patients and clinicians," said Scott Odgers, Senior Director Strategic Accounts, Dexcom. "We're proud to integrate with Rimidi and leverage our innovative CGM technologies to further empower patients to take control of health."
For more information on Rimidi and its newly enhanced diabetes management platform, visit rimidi.com/solutions/diabetes.
Members of the Rimidi and Dexcom teams will also be at the American Diabetes Association's 83rd Scientific Sessions 2023 in San Diego, CA from June 23-26. To book a meeting with Dr. Ide at the conference, please reach out to [email protected].
About Rimidi
Created by doctors, Rimidi's leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and achieve quality objectives. By bringing together clinical decision support, remote patient monitoring and patient reported outcomes in a unified, composable, FHIR-based platform, Rimidi supports a broad range of clinical use cases and institutional priorities across large and small healthcare organizations. For more information, visit rimidi.com and follow us on Twitter and LinkedIn.
Media Contact
Michelle Rand, Alloy, on behalf of Rimidi, 855.300.8209, [email protected]
SOURCE Rimidi
Share this article